Decreased immunoreactivity of von Willebrand factor may reflect persistent nature of the endothelial dysfunction in non-ischemic heart failure

Edyta Reichman-Warmusz1, Marlena Brzozowa-Zasada1, Celina Wojciechowska2, Damian Dudek1,3, Oliwia Warmusz1, Romuald Wojnicz1

1Department of Histology and Cell Pathology, Medical University of Silesia in Katowice, School of Medicine with the Division of Dentistry, Zabrze, Poland
2Second Department of Cardiology, Medical University of Silesia, School of Medicine with the Division of Dentistry, Zabrze, Poland
3Ambulatory Oral Surgery and Implantology, Torun, Poland

Abstract

Introduction. Endothelial dysfunction is a critical part of heart failure (HF) pathophysiology. It is not clear, however, whether it is present at the similar level in the early and late HF stages.

Material and methods. von Willebrand factor (vWF) and its mRNA levels in biopsies of non-ischemic patients with HF secondary to dilated cardiomyopathy were studied. Consecutive patients with HF were divided into two groups: group A with disease duration \( \leq 12 \) months (\( n = 59 \)) and group B with disease duration > 12 months (\( n = 68 \)). The immunoreactivity of the vWF was compared with autopsy sections of 19 control cases. Tissue vWF gene expression was analyzed at the mRNA level by RT-PCR.

Results. In the group A, there was lower vWF immunoreactivity in the coronary microvessels compared to the group B \[1.5 (1.0–2.0) \text{ vs } 2.0 (1.5–2.4), P = 0.001\]. In the control group, only weak vWF expression was observed. Protein expression was not accompanied by vWF mRNA whose levels were significantly higher in the Group A as compared to the Group B \[14671 (4932–51561) \text{ vs. } 3643 (185.3–9030.8), P = 0.005\]. Protein vWF expression was inversely associated with its mRNA levels \( r = –0.34, P = 0.04 \).

Conclusions. High myocardial protein expression of vWF in patients with long-lasting HF symptoms may highlight the persistent nature of endothelial dysfunction in such a cohort of patients. (Folia Histochemica et Cytobiologica 2021, Vol. 59, No. 2, 108–113)

Key words: heart failure; dilated cardiomyopathy; endomyocardial biopsy; endothelial dysfunction; von Willebrand factor; qPCR; IHC

Introduction

Heart failure is defined as a complex clinical syndrome of impaired heart functions and is a leading cause of morbidity and mortality in developed countries. The prevalence of heart failure (HF) worldwide continues to increase, maintaining high rates of morbidity and mortality despite the use of multiple evidence-based therapeutic strategies [1]. The main characteristic of HF is its multifaceted clinical presentation and its progressive nature [2].

For a long time disturbances in the coronary microcirculation have been postulated to contribute to HF development and progression [3, 4]. It is believed to be a consequence of endothelial dysfunction through loss of its multifaceted regulatory properties [5, 6].
a result, an abnormal coronary microcirculatory flow may cause impairment of myocardial perfusion and metabolic changes compatible with local myocardial ischemia [7, 8]. More recently it has been reported that endothelial dysfunction in HF independently predicts morbidity and mortality in this cohort of patients [9, 10]. The exact mechanisms for endothelial dysfunction in HF are unclear. However, it is believed to be the result of lost nitric oxide-dependent vasodilatation, a proinflammatory state, and its prothrombotic properties [11, 12].

Von Willebrand factor (vWF) is a large multimeric glycoprotein produced by endothelial and megakaryocytes that is present in endothelial cells (Weibel-Palade bodies), the subendothelial matrix, platelets and blood plasma [13]. Its main function is mediation of platelet aggregation at the site of vascular injury and thrombus growth. Thus, given the ubiquitous involvement of vWF in local vascular homeostasis, it is not surprising that this factor plays an important role in HF pathogenesis [14]. As vWF release is increased when endothelial cells are injured, it has been proposed as a marker of endothelial dysfunction [15–17]. It is not clear, however, whether endothelial dysfunction is present to the same extent in the HF of short or long duration.

Accordingly, the aim of this study was to clarify this issue by examining biopsy specimens of patients with short and long-standing HF duration by immunohistochemistry (IHC) and RT-qPCR.

Materials and methods

Patients and material collection. Patients. One hundred and twenty-seven patients with stable, non-ischemic HF (NYHA I to III, LVEF < 40%), attributable to dilated cardiomyopathy were prospectively studied. Right ventricular endomyocardial biopsy was carried out in all patients. Patients were divided into two groups: Group A with HF duration ≤ 12 months (n = 59; 50 men and 9 women), and Group B with HF duration > 12 months (n = 68; 63 men and 5 women). In addition, we used the cardiac autopsy sections of 19 young cases that suddenly died in car crashes (11 men, 8 women, mean age of 33.5 ± 6.8 years). This group served as a control for immunohistochemical staining of vWF protein.

All the HF patients had selective coronary angiography to exclude ischemic etiology of HF. In addition, none of the studied patients had other potential causes of HF; including valvular (except relative mitral and/or tricuspid regurgitation), endocrine disease (except impaired glucose tolerance), endocarditis disease (except impaired glucose tolerance), advanced renal disease, and reported drug or alcohol abuse. All of them were on typical therapeutic regimens for HF including loop diuretics (torasemide and/or furosemide), ACE inhibitors or ATII blockers, β-blockers, and spironolactone for at least 6 months prior to the biopsy. Apart from standard HF therapy, none of the patients was treated with oral anticoagulants, statins and antiarrhythmic drugs or had an electrical device implanted before the biopsy was done. Four to five endomyocardial biopsies were obtained from each patient. All biopsies except one specimen dedicated for molecular biology, were fixed for 20 min in cold acetone, immersed in embedding medium (OCT Compound, Miles Inc., Sakura Finetek, USA) and cryo-preserved in liquid nitrogen until tested.

This study was carried out in accordance with the Helsinki Declaration, and the study design was approved by the Institutional Ethics Committee (NN-6501-7/07). All patients gave their informed consent.

Immunohistochemistry. For IHC, specimens were cut serially into 5 mm thick slices on a Cryotome FSE® Thermo Shandon (Thermo Scientific-Shandon, Lipshaw, PA, USA), air-dried at room temperature and incubated with murine monoclonal anti-vWF antibodies (clone F8/86); dilution 1:300; DAKO). In addition, to exclude myocarditis, frozen sections were incubated with murine monoclonal antihuman antibodies (Abs): anti-HLA-class II (DR antigens), Alpha chain (clone TAL.1B5), anti-HLA-class I (ABC antigens) (clone W6/32), anti-CD3 for T lymphocytes (Clone T3-4B5), and anti-CD68 (clone EBM11). All antibodies were from DAKO A/S, Glostrup, Denmark. The dilution of the primary antibody was verified in our laboratory in a series of pilot experiments.

The En-Vision method (DAKO En-Vision Kit®/Alkaline Phosphatase detection system) was used according to the manufacturer’s instructions. The bound primary antibody was detected using New Fuchsinsubstrate System (DAKO A/S). The primary antibody was omitted from negative control slides. To suppress nonspecific staining due to endogenous alkaline phosphatase activity, Levamisole was used at a final concentration of 0.2 mM. The sections were counterstained with Mayer’s hematoxylin.

For the semiquantitative assessment of the intensity of vWF microvascular staining, the score index at 200x magnification was as follows: (1+) weak staining in a few vessels; (2+) moderate staining in most microvessels and (3+) strong staining in all microvessels. All IHC analyses were performed by two investigators independently, blinded to clinical features. The inter-observer variability of immunohistochemical examinations for vWF was < 3%. Histological results were obtained with the use of Nikon Eclipse 80i microscope with DS-Fi1 digital camera and NIS Elements software from Nikon (Tokyo, Japan).

Quantitative real-time PCR (qPCR). For the real-time PCR examination of the vWF RNA, total RNA was extracted from myocardial specimens by the Trizol® reagent (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA).
according to the manufacturer's protocol. The quality of the RNA was assessed by gel electrophoresis and the quantitative analysis of RNA extracts was performed spectrophotometrically using a GeneQuant™ pro RNA/DNA Calculator (Amersham Biosciences, Little Chalfont, United Kingdom). The quantitative analysis was carried out with the use of an Opticon™ DNA Engine Continuous Fluorescence detector (MJ Research, Reno, NV, United States). The expression of the mRNA for vWF was determined by quantitative real-time PCR (forward sequence: CCTTGAATCCCAGTGACCCTGA, reverse sequence: GGTTCCGAGATGTCCTCCACAT). The PCRs of RNA extracted from biopsy specimens were carried out in 25 cycles. All PCR reactions were terminated by a final elongation step of 10 min at 72°C. All samples were tested in triplicate. The PCR amplicons was determined after each round of amplification, using the fluorescent dye SYBR-Green (Sybr Green Quantitect RT-PCR Kit; Qiagen, Venlo, Netherlands). Glycerinaldehyde-3-phosphate dehydrogenase (GAPDH) and β-actin (TaqMan® DNA template reagents kit; PE Applied Biosystems) were included to monitor RT-PCR. To assess vWF gene expression in the studied groups we used the standard curve method to determine the absolute mRNA quantity in the samples. PCR products were separated on 6% polyacrylamide gel and visualized using silver staining. The length of the amplified fragments was assessed by analysis with Quantity One 4.6.9 software (Molecular Imager ChemiDOC XRS+, BIO-RAD, Hercules, CA, USA).

**Statistical analysis.** The statistical analysis was made with the SPSS version 16.0 software package (SPSS, Inc., Chicago, IL, USA). Data were analyzed by the Shapiro-Wilk test to determine distribution. Normally distributed data were analyzed using t-test (based on normal distribution tested by the Kolmogorov-Smirnov test) and expressed as mean ± SD. Not normally distributed data are presented as median with interquartile range (IQR; 25th and 75th percentiles). To compare not normally distributed data of vWF immunoreactivity in all studied groups, Kruskal-Wallis analysis of ranks and post hoc test of the Mann-Whitney U test were used. Associations between them were done by the Kendall’s tau test. Differences were considered statistically significant at *P* < 0.05.

### Results

Clinical and demographic details of the study patients are shown in Table 1. Except for the HF duration, there was no difference in age, gender, etiology of HF, and medications used between the study groups. For the overall group of patients, the average time of symptoms was 19 months (ranging from 0.6 months to 8 years), and all the patients were in NYHA class I, II or III.

In the control cryostat sections, only weak and focally distributed expression of vWF was observed (Fig. 1A and 1B). The cryostat sections taken from HF patients presented both basal and strong immunoreactivity of vWF (Fig. 1C and 1D). In group A (HF duration ≤ 12 months), there was lower pheno-

### Table 1. Baseline characteristics of the patients

<table>
<thead>
<tr>
<th></th>
<th>All patients n = 127</th>
<th>Group A n = 59</th>
<th>Group B n = 68</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age [y]</td>
<td>44.2 ± 11.7</td>
<td>40.7 ± 10.7</td>
<td>42.4 ± 0.9</td>
<td>NS</td>
</tr>
<tr>
<td>Sex, male/female</td>
<td>113/14</td>
<td>50/9</td>
<td>63/5</td>
<td>NS</td>
</tr>
<tr>
<td>Time of HF duration [mth]</td>
<td>29.5 ± 38.9</td>
<td>7.6 ± 2.7</td>
<td>52.1 ± 21.9</td>
<td>–</td>
</tr>
<tr>
<td>Atrial fibrillation, n [%]</td>
<td>21 (16.5)</td>
<td>9 (15.3)</td>
<td>12 (17.6)</td>
<td>NS</td>
</tr>
<tr>
<td>BMI [kg/m²]</td>
<td>26.3 ± 4.6</td>
<td>25.5 ± 4.4</td>
<td>26.2 ± 5.2</td>
<td>NS</td>
</tr>
<tr>
<td>NYHA class, n, I/II/III</td>
<td>4/110/13</td>
<td>3/51/5</td>
<td>1/59/8</td>
<td>NS</td>
</tr>
<tr>
<td>LVEF [%]</td>
<td>28.1 ± 7.0</td>
<td>29.2 ± 6.4</td>
<td>27.6 ± 7.5</td>
<td>NS</td>
</tr>
<tr>
<td>LVEDD [mm]</td>
<td>68.6 ± 10.3</td>
<td>67.5 ± 11.3</td>
<td>69.6 ± 0.1</td>
<td>NS</td>
</tr>
<tr>
<td>Serum vWF [%]</td>
<td>156.3 ± 63.5</td>
<td>162.8 ± 67.3</td>
<td>149.4 ± 60.3</td>
<td>NS</td>
</tr>
<tr>
<td>Fibrinogen [mg/dL]</td>
<td>367.2 ± 95.3</td>
<td>376.0 ± 107.1</td>
<td>357.9 ± 81.5</td>
<td>NS</td>
</tr>
<tr>
<td>CRP [mg/dL]</td>
<td>(–)</td>
<td>1.42 (0.14–30.2)</td>
<td>1.64 (0.17–21.5)</td>
<td>NS</td>
</tr>
<tr>
<td>UA [µmol/L]</td>
<td>436.9 ± 111.9</td>
<td>440.5 ± 114.4</td>
<td>439.0 ± 114.6</td>
<td>NS</td>
</tr>
<tr>
<td>NT-proBNP [pg/mL], median [1st-3rd quartile]</td>
<td>898.9 (356.5–2338)</td>
<td>886.8 (365–3004)</td>
<td>838.3 (248.1–2757)</td>
<td>NS</td>
</tr>
</tbody>
</table>

Values are expressed as mean ± SD or as indicated, NS — non-significant. Group A — HF duration ≤ 12 mo, group B — HF duration > 12 mo. Abbreviations: BMI — body mass index; CRP — C-reactive protein; HF — heart failure; LVEF — left ventricle ejection fraction; LVEDD — left ventricle end diastolic dimension; NYHA — New York Heart Association; NT-proBNP — amino-terminal pro-B-type natriuretic peptide; UA — uric acid
Von Willebrand factor in heart failure

Figure 1. Representative examples of vWF immunostaining in the study groups: Group A — heart failure duration ≤ 12 mths, Group B — heart failure duration > 12 mths. The basal expression of vWF on sparse microvessels (arrows) in the control subjects (original magnification 100×). (C and D) The strong up-regulation of vWF on microvascular endothelium in two HF subjects from the Group B (red color; original magnification × 100).

Figure 2. Comparison of the immunoreactivity index (0–3+) for vWF between the Group A (HF duration ≤ 12 mths) and Group B (HF duration > 12 mths). Values are medians with IQRs. *P < 0.001. The Immunoreactivity index was calculated as described in Methods.

Discussion

To the best of our knowledge, we have for the first time observed a relationship between up-regulation of vWF protein immunoreactivity in the myocardium of patients with non-ischemic HF secondary to dilated cardiomyopathy and the disease duration.

type vWF expression in the coronary microvessels in comparison with group B (HF duration > 12 months) [1.5 (1.0–2.0) vs. 2.0 (1.5–2.4), P < 0.001] (Fig. 2). Unexpectedly, the IHC data was not collaborated with the vWF mRNA copy quantity which were present in a wide range in both study groups and were significantly lower in patients with long-standing disease [median 14671 (range 4932–51561) vs. 3643 (185.3–9030.8), P = 0.005] (Fig. 3). In addition, vWF protein immunoreactivity was inversely associated with vWF mRNA levels (r = −0.34, P = 0.04).
It was known that vWF, stored mainly in the Weibel-Palade bodies of endothelial cells, can be mobilized rapidly after endothelial cell activation [6]. In addition, among hemostatic mediators, vWF plays a key role in platelet aggregation and stabilization of circulating clotting factors [13].

Most previously published reports focused on soluble vWF levels in plasma of HF patients [18, 19]. Following the observations by Lip et al., HF were found to substantially increase plasma vWF concentrations and appeared to be highest among patients with acute or recently decompensated HF [20]. Of note, in this study the risk of stroke and thromboembolism was substantially increased in patients with congestive HF concomitant with atrial fibrillation. In another study by Gibbs et al., patients with persistently increased serum concentrations of vWF and higher degree of endothelial dysfunction had a higher risk of thrombosis [21]. Studies by Kleber et al. have shown that plasma vWF was an independent predictor of the long-term outcome in these patients [18].

Little attention has been paid to tissue vWF expression in HF patients. Fukuchi et al. [22] have provided evidence that stronger tissue immunoreactivity for vWF in the endocardial endothelium in overloaded human atrial appendage may be a local predisposing factor for intra-atrial thrombogenesis. Our findings extend these results, revealing persistent vWF expression on the coronary microvessels in HF patients. Although hypothetical, this may reflect the role of endothelial dysfunction in perpetuating myocardial failure in such a cohort of patients.

The increased vWF protein immunoreactivity together with diminished levels of mRNA in long-lasting HF in our study seems to be only on the surface discrepant. Taking into consideration the results of previous study, it is likely that it may reflect lower turnover of this protein rather than an increase in its synthesis in the endothelium. Indeed, it was reported that activity of plasma metalloprotease ADAMTS13 which cleaves vWF was decreased in HF. Such low ADAMTS13 activities were accompanied with high vWF serum levels of HF patients [14].

It has to be kept in mind that the size of sample in our study is limited. Therefore this study may not have been powered enough to verify negative relationship of phenotype protein expression and mRNA levels found. Moreover, we did not perform follow-up biopsies to better reflect time-related changes in protein and mRNA expressions. Our findings cannot be extrapolated to patients with more severe disease or unstable conditions.

Despite these limitations in the present study we demonstrated for the first time the persistent nature of vWF protein expression in the coronary microvessels of non-ischemic HF patients. Considering the results, it may be hypothesized that some of these patients are stranded on a self-perpetuating course of advancing heart failure. Thus, persistent endothelial dysfunction as reflected by the up-regulation of myocardial vWF protein expression in patients with long-standing HF might contribute to local hypercoagulability and hence actively contributes to the disease progression.

Acknowledgment
This study was supported by grant from Medical University of Silesia, Katowice, Poland (KNW-1-066/N/7/O and KNW-1-113/K/8/O).

Conflict of interest
The authors declare no conflict of interest.

References


Submitted: 30 November, 2020
Accepted after reviews: 29 April, 2021
Available as AoP: 18 May, 2021

© Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2021
10.5603/FHC.a2021.0012
ISSN 0239-8508, e-ISSN 1897-5631

www.journals.viamedica.pl/folia_histochemica_cytobiologica